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A B S T R A C T   
A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they have to be stored at 
(ultra)low temperatures. Understanding the root cause of the instability of these vaccines may help to rationally 
improve mRNA-LNP product stability and thereby ease the temperature conditions for storage. In this review we 
discuss proposed structures of mRNA-LNPs, factors that impact mRNA-LNP stability and strategies to optimize 
mRNA-LNP product stability. Analysis of mRNA-LNP structures reveals that mRNA, the ionizable cationic lipid 
and water are present in the LNP core. The neutral helper lipids are mainly positioned in the outer, encapsu-
lating, wall. mRNA hydrolysis is the determining factor for mRNA-LNP instability. It is currently unclear how 
water in the LNP core interacts with the mRNA and to what extent the degradation prone sites of mRNA are 
protected through a coat of ionizable cationic lipids. To improve the stability of mRNA-LNP vaccines, optimi-
zation of the mRNA nucleotide composition should be prioritized. Secondly, a better understanding of the milieu 
the mRNA is exposed to in the core of LNPs may help to rationalize adjustments to the LNP structure to preserve 
mRNA integrity. Moreover, drying techniques, such as lyophilization, are promising options still to be explored.   
1. Introduction 
Of the many COVID-19 vaccines under development, the two vac-
cines that have shown the most promising results in preventing COVID- 
19 infection represent a new class of vaccine products: they are 
composed of messenger ribonucleic acid (mRNA) strands encapsulated 
in lipid nanoparticles (LNPs). The efficacy of these mRNA vaccines 
developed by BioNTech/Pfizer and Moderna is about 95% (Baden et al., 
2021; Polack et al., 2020) and they were the first mRNA vaccines to 
receive ‘emergency use authorization’ (by FDA) and ‘conditional 
approval’ by EMA. These mRNA COVID-19 vaccines encode the viral 
Spike (S) glycoprotein of SARS-CoV-2 that includes two proline sub-
stitutions (K986P and V987P mutations), in order to stabilize the pre-
fusion conformation of the glycoprotein (Wrapp et al., 2020). Upon 
intramuscular (IM) administration, the LNP system enables the uptake 
by host cells and the delivery of mRNA inside the cytosol, where the 
translation of the mRNA sequence into the S protein occurs in the ri-
bosomes. After post-translation processing by the host cells, the S pro-
tein is presented as a membrane-bound antigen in its prefusion 
conformation at the cellular surface, providing the antigen target for B 
cells. In addition, part of the temporally produced Spike proteins enter 
antigen presentation pathways, providing antigen recognition by T cells 
via MHC presentation of T-cell epitopes (Verbeke et al., 2021). The EMA 
assessment report formulates the mechanism of action of mRNA vac-
cines at the injection site as follows: ‘Administration of LNP-formulated 
RNA vaccines IM results in transient local inflammation that drives 
recruitment of neutrophils and antigen presenting cells (APCs) to the site 
of delivery. Recruited APCs are capable of LNP uptake and protein 
expression and can subsequently migrate to the local draining lymph 
nodes where T cell priming occurs (EMA, 2020a).’ Because of this 
inherent innate immune activity, it is not necessary to formulate the 
mRNA vaccines with additional adjuvants. Interestingly, Pfizer/ 
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BioNTech and Moderna specifically use nucleoside-modified mRNA that 
decrease (rather than increase) the inherent mRNA immunogenicity, 
underlining the need to properly balance the innate immune activity of 
mRNA vaccines (see below). The in vivo antigen production post- 
administration that can be achieved with mRNA vaccines, together 
with the self-adjuvant properties of mRNA-LNP vaccines, ultimately 
leads to the efficient generation of neutralizing antibody responses and 
cellular immunity, decreasing the risk of developing COVID-19 for the 
vaccine recipients. 
mRNA vaccines have several benefits over other types of vaccines. A 
general advantage of mRNA vaccines is that their development is rela-
tively fast, as mRNA-LNPs are a true platform technology. After identi-
fication of the protective protein antigen(s) and sequencing the 
corresponding gene(s), the mRNA can be made within weeks (Jackson 
et al., 2020). As the mRNAs encoding different antigens are chemically 
and physically highly similar, formulation design and manufacturing 
processes of new mRNA vaccines follow the same steps (Petsch et al., 
2012). Compared to replication deficient viral vectors, mRNA vaccines 
may be more efficacious for COVID-19 prevention. Unlike viral vector- 
based vaccines, they don’t generate immunity against the carrier. In 
this regard mRNA vaccines are similar to desoxyribonucleic acid (DNA)- 
based vaccines. DNA vaccines, however, still have a minute chance of 
potential genome integration. Moreover, in contrast to mRNA vaccines, 
DNA vaccines have shown rather low immunogenicity in early clinical 
trials, possibly because DNA-based vaccines need to gain access to the 
nucleus to exert their action, complicating efficient delivery. Overall, 
flexible design, standardized production processes and relatively short- 
lived cytoplasmic presence make mRNA vaccines very powerful, espe-
cially in a pandemic situation with rapidly mutating viruses. 
However, one of the greatest challenges encountered when devel-
oping mRNA vaccines is their poor stability. Currently, most mRNA 
vaccines are administered IM, where the mRNA that is taken up by host 
cells leads to antigen expression (Hassett et al., 2019). Early research on 
mRNA vaccines has demonstrated that naked mRNA is quickly degraded 
after administration (Pardi et al., 2015; Wayment-Steele et al., 2020). 
Consequently, over the last few years efforts were made to improve the 
in vivo stability of mRNA after administration. This led to ways to 
optimize the mRNA structure by slowing down its degradation (see 
under section ‘mRNA stability’). Another successful and currently 
widely used approach is to encapsulate and protect the mRNA in LNPs 
(Pardi et al., 2015). This reduces premature mRNA degradation after 
administration and enhances delivery to the cytosol of antigen- 
presenting cells (Liang et al., 2017; Lindsay et al., 2019). 
Although progress has been made to enhance the stability in vivo and 
efficacy of mRNA-LNP vaccines, much less attention has been paid to 
their stability during storage (Crommelin et al., 2021). In order to 
effectively distribute a vaccine worldwide, it should have a sufficiently 
long shelf life, preferably at refrigerator temperatures (2–8 ◦C) or above. 
Currently, hardly any data is available in the public domain on what 
happens when mRNA-LNP formulations are stored for long periods of 
time. Moreover, it is unclear to what extent entrapping mRNA within 
LNPs influences the storage stability of the mRNA vaccine. Additionally, 
very little is known about the structure and morphology of LNPs 
formulated with mRNA, the chemical stability of the LNP components 
and the colloidal stability of the mRNA-LNP system. What is known now 
is that in order to store the current mRNA COVID-19 vaccines for longer 
periods of time, they have to be frozen. The current mRNA COVID-19 
vaccines of Moderna and BioNTech/Pfizer have to be kept between 
− 15 and − 25 ◦C and between − 60 and − 90 ◦C, respectively (EMA, 
2020a, 2021). To date, the degradation processes and the reasons why 
storage temperature requirements differ, are not fully understood. 
The requirement of storing the mRNA-LNPs in a frozen state hampers 
vaccine distribution. Especially, the very low temperature of − 60 to 
− 90 ◦C is a major obstacle when it comes to vaccine transport, storage 
and distribution among end-users worldwide. Most other vaccines can 
be stored at 2–8 ◦C. Clearly, there is a need and opportunity to find ways 
of stabilizing mRNA-LNP vaccines to allow non-frozen storage. This 
review provides an overview of approaches to make mRNA vaccines 
more stable, so that they can be stored longer at less extreme tempera-
tures. To explore the topic, the characteristics of mRNA-LNP vaccines 
and their influence on storage stability are discussed. This information is 
used to identify the reasons for mRNA vaccine instability and to explore 
technological options for stability improvement. 
2. Overview of mRNA vaccines 
The composition of mRNA-LNP vaccines is fundamental to their 
stability. In the development of vaccines against SARS-CoV-2, a variety 
of different mRNA vaccine candidates have been created. Currently, 
there are 10 different mRNA COVID-19 vaccines that have progressed to 
clinical trials (World Health Organization, 2021). The SARS-CoV-2 
mRNA vaccines either use conventional mRNA or self-amplifying 
mRNA (SAM). There are currently three ‘conventional’ mRNA vac-
cines in use or in advanced clinical trials that encode the full S protein. 
These are the mRNA-1273 vaccine by Moderna, BNT162b2/Comirnaty 
by BioNTech/Pfizer and CVnCoV by CureVac (Table 1). A detailed 
comparison of these three mRNA COVID-19 vaccines including their 
differences and similarities in mRNA structure and LNP design has been 
provided in several other reviews (Kim et al., 2021; Verbeke et al., 
2021). The following sections aim to give an overview of the function 
and characteristics of the mRNA component and the LNP delivery sys-
tem in these vaccines, as they play a critical role in the stability of mRNA 
vaccines, both upon in vivo administration and during storage. 
2.1. mRNA engineering for optimum in vivo stability and translation 
capacity 
Because of the negative charges on its phosphate groups, mRNA is a 
polyanionic macromolecule in pH ranges typically used for parenterals 
(Lipfert et al., 2014). A first obstacle for mRNA vaccines is that naked 
mRNA is quickly degraded upon injection by ribonucleases (RNase), 
which are abundant in the extracellular environment. Second, the 
internalization of mRNA inside the cell is detected by intracellular RNA 
sensors, including endosomal Toll-like receptors (TLR) and cytoplasmic 
nucleic acid sensors. Binding of mRNA to these host defense receptors 
activates innate immune pathways, leading to the expression of hun-
dreds of genes. One the one hand, this may provide an adjuvant effect on 
the vaccine potency. On the other hand, it establishes an antiviral state 
in cells, which strongly reduces the mRNA intracellular stability and 
translation (Pepini et al., 2017). Following internalization, mRNA 
strands need to be recruited into the ribosomes to enable the expression 
of the encoded protein. The protein synthesis rate and the functional 
half-life of mRNA can be drastically increased through mRNA engi-
neering. The typical elements of an mRNA strand for inclusion in an 
mRNA vaccine are schematically presented in Fig. 1. 
Many efforts have been made to increase the in vivo stability and 
translation capacity of the mRNA molecule, while avoiding unwanted 
innate immune activation. One prevalent idea is that this can be ach-
ieved by optimizing the regulatory regions of the mRNA: the 5′ cap, 
poly-A tail and untranslated regions (UTRs). The UTRs are parts of the 
mRNA that flank the coding region of the mRNA and regulate its sta-
bility and translation. The poly-A tail also regulates stability, as its 
shortening and eventual removal leads to mRNA degradation. The 5′ cap 
structure is important for protein production and the recruitment of 
translation initiation factors (Pardi et al., 2018). Furthermore, mRNA 
with maximized GC (guanine-cytosine) content in combination with 
codon optimization, i.e., selection of ‘frequent codons’ in the coding 
region, leads to enhanced stability and translation (Thess et al., 2015). 
Another critical determinant is the secondary structure of mRNA, which 
can be stabilized by changing the primary sequence through codon 
optimizations and computational tools. Building secondary structures in 
the mRNA –except in the 5′ UTR region– by choosing ‘highly structured 
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coding sequences’ leads to higher translation in vivo as well, because of a 
longer functional half-life (Mauger et al., 2019). Alternatively, Mauger 
et al. demonstrated that the incorporation of naturally occurring 
modified uridines, such as the use of 1-methyl-pseudouridine (m1Ψ) 
instead of uridine, induces global changes in the secondary structure of 
mRNA which correlated with high protein expression. Importantly, the 
Table 1 
Information about the three mRNA-LNP drug products that are presently used or in clinical phase III trials. For comparison reasons, drug product information for 
Onpattro (an siRNA-LNP drug product) has been added.  
Category siRNA Pfizer-BioNTech mRNA vaccine Moderna mRNA vaccine Curevac mRNA 
vaccine 
candidate 
Name product Onpattro * 
patisiran 
BNT162b2; Comirnaty mRNA-1273 CVnCoV 
mRNA dose; route of 
administration 



















0.05 mg ALC-0159 = 2- 
[(polyethylene glycol)-2000]-N,N 
ditetradecylacetamide 
0.09 mg 1,2-Distearoyl-sn-glycero- 
3-phosphocholine (DSPC) 
0.2 mg Cholesterol 
SM-102 (heptadecan-9-yl 8-((2-hydroxyethyl) (6- 
oxo-6-(undecyloxy) hexyl) amino) octanoate} 
PEG2000-DMG = 1- 
monomethoxypolyethyleneglycol-2,3- 
dimyristylglycerol with polyethylene glycol of 
average molecular weight 2000 









Molar lipid ratios (%) 
ionizable cationic 
lipid : neutral lipid : 
cholesterol : PEG- 
ylated lipid 
50:10:38.5:1.5 46.3:9.4:42.7:1.6 50:10:38.5:1.5 50:10:38.5:1.5 
Molar N/P ratiosa 3 6 6b 6b 
Buffer Potassium phosphate, monobasic, 
anhydrous 
Sodium phosphate, dibasic, 
heptahydrate 
pH ~ 7 
0.01 mg Potassium dihydrogen 
phosphate 
0.07 mg Disodium hydrogen 





Other excipients Sodium chloride 
Water for injection 
0.01 mg Potassium chloride 
0.36 mg Sodium chloride 
6 mg Sucrose 
Water for injection 
Sodium acetate 
Sucrose 
Water for injection 
Saline 
*NDA 210922 ONPATTRO (patisiran) Lipid Complex Injection; Addendum to Drug Product Quality Review (FDA, 2017). 
a N = ionizable cationic lipid (nitrogen), P = nucleotide (phosphate). 
b Estimate. 
Fig. 1. Structural elements of in vitro transcribed (IVT) mRNA. Each of these elements can be optimized and modified in order to modulate the stability, translation 
capacity, and immune-stimulatory profile of mRNA. Courtesy of Verbeke et al. (2019). 
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introduction of these modified uridines inside the mRNA construct is 
currently the most efficient way to minimize the cellular recognition of 
mRNA by RNA-binding proteins that are involved in the innate immune 
reaction to foreign mRNA. This, in turn, enhances biological stability 
and translational capacity, while reducing the reactogenicity of mRNA 
vaccines. Moreover, there are also indications that m1Ψ increases base 
stacking and the melting point of mRNA, thereby making mRNA more 
stable (Mauger et al., 2019; Zhao and He, 2015). This could mean that 
the incorporation of 1mΨ, as is done for the COVID-19 vaccines from 
Moderna and BioNTech/Pfizer, also affects the stability of mRNA before 
administration. CureVac followed a different path, as outlined by Thess 
et al. (Thess et al., 2015). An interesting analysis of the choices CureVac 
made in engineering the CVnCoV mRNA was recently published 
(Hubert, 2021). However, even when these structural elements are 
optimized, IM injection of naked mRNA through a syringe does not lead 
to a robust immune response, probably because of the poor cell trans-
fection capacity of naked mRNA and the susceptibility to RNase (Pardi 
et al., 2015). Importantly, this illustrates that optimization of only the 
mRNA structure is not sufficient for creating effective mRNA vaccines: 
additional protection and delivery systems are needed (Kauffman et al., 
2016; Sahin et al., 2014). 
The other type of mRNA vaccines, SAMs, do not only encode the 
target antigen but also RNA polymerase encoding ‘self-amplifying’ fac-
tors derived from Alphavirus. Typically, they consist of 9 kb mRNA 
nucleotides compared to 2–4 kb for non-replicating mRNA vaccines. The 
SAM vaccine candidates were developed with the intent of forgoing the 
typical ‘prime-boost’ regimen of a two-dose strategy and instead 
focusing on a single injection per recipient. Because of their replication 
competence, the injected dose for SAM vaccines is lower than for con-
ventional mRNA vaccines and one dose might be sufficient for protec-
tion (Erasmus et al., 2020; Vogel et al., 2018). When SAMs are translated 
in the host cell, an RNA replicase synthesizes negative-sense RNA in-
termediates complementary to the coding mRNA template (Fig. 1). 
These are in turn transcribed to many coding mRNA molecules, leading 
to prolonged and enhanced antigen expression (Bloom et al., 2020). 
Both SAM vaccines encode the full S protein and the highest dose for 
these vaccines in clinical trials was more than tenfold lower than the 
typical doses used for the conventional mRNA vaccines (Ward and 
McCormack, 2021). The two SAM vaccines in clinical development are 
nCoVsaRNA by the Imperial College London and ARCT-021 by 
Arcturus/Duke-NUS (both as mRNA-LNP). 
2.2. LNPs as delivery system 
To overcome these transfection problems with naked mRNA, pro-
tecting delivery systems have been developed. Currently, the leading 
mRNA COVID-19 vaccines (Table 1) are all utilizing LNP technology. 
This illustrates the successes achieved with this type of nanoparticle to 
stabilize mRNA and successfully deliver it into cells (Pardi et al., 2015). 
The LNPs in mRNA COVID-19 vaccines consist of four main components 
(cf. Table 1): a neutral phospholipid, cholesterol, a polyethylene-glycol 
(PEG)-lipid, and an ionizable cationic lipid. The latter contains posi-
tively charged ionizable amine groups (at low pH) to interact with the 
anionic mRNA during particle formation and also facilitate membrane 
fusion during internalization (Evers et al., 2018; Reichmuth et al., 
2016). In addition, PEG-lipid is used to control the particle size and act 
as a steric barrier to prevent aggregation during storage. Together with 
the mRNA, these components form particles of about 60–100 nm in size 
by using a rapid mixing production technique (Evers et al., 2018). The 
SARS-CoV-2 vaccine candidates nCoVsaRNA and ARCoV, for example, 
have average particle sizes of 75 nm and 89 nm, respectively (McKay 
et al., 2020; N.-N. Zhang et al., 2020). 
A key aspect of LNPs and the characteristic that makes them different 
from liposomes (spherical vesicles with at least one lipid bilayer and an 
aqueous core) is the presence of lipids in the core, although data from 
several studies indicate that water is also present to some extent (Arteta 
et al., 2018; Kulkarni et al., 2018; Brader et al., 2021). This would mean 
that the mRNA could be exposed to an aqueous environment, even when 
it is encapsulated. This type of core structure has been previously found 
in both unloaded and siRNA (small interfering RNA) containing LNPs, as 
demonstrated by cryogenic transmission electron microscopy (cryo- 
TEM) (Kulkarni et al., 2019, 2018). Similarly, studies of mRNA-LNPs 
have shown electron dense cores (Fig. 2) (Arteta et al., 2018; Eygeris 
et al., 2020; Leung et al., 2015; Patel et al., 2020; Tanaka et al., 2020). 
Thionine was used for cryo-TEM contrast enhancement (Brader et al., 
2021). 
Although their lipid core is a common feature of mRNA-LNPs, 
characteristics of the exact structure of this core and its dependence 
on lipid ingredients (molar ratios) and the localization of the mRNA are 
still under debate (see Fig. 3). mRNA is certainly located inside the LNPs, 
as determined by the RiboGreen assay. RiboGreen is a dye that exhibits 
fluorescence when bound to single stranded mRNA, but cannot enter the 
LNPs. In mRNA-LNP formulations, such as those used in mRNA vaccines, 
the fraction of accessible mRNA is very low (Arteta et al., 2018; Patel 
et al., 2020) and thus, encapsulation efficiencies, derived from Ribo-
Green assays, are typically > 90%. Taken together, the cryo-TEM (Fig. 2) 
and encapsulation evidence shows that the mRNA-LNPs form nano-
particles with encapsulated mRNA that is protected from the external 
medium. There are 3 models proposed for the structure of mRNA 
encapsulated by LNPs; these mainly originate from siRNA-LNPs analysis 
(Fig. 3). 
The dawn of mRNA vaccA limitation of this is that the encapsulated 
cargo affects the structure of LNPs: siRNA is very different from mRNA in 
structure and size (Table 2) and the molar N/P (ionizable cationic lipid 
over phosphate) molar ratios differ, 3 versus 6, respectively (Table 1). 
mRNA is at least 100-fold larger than siRNA and this affects the structure 
of the LNPs. Besides, there are indications that mRNA is located in the 
core of the LNPs and siRNA more towards the surface and mRNA can 
form ‘blebs’ (Fig. 2) (Viger-Gravel et al., 2018). The composition of the 
bleb part of the LNP is a matter of debate (Leung et al., 2015; Brader 
et al., 2021). The latter state: “mRNA can dissociate from the charged 
lipid to reside within a solvent-filled bleb compartment.” 
The multilamellar vesicle model for mRNA-LNPs (Fig. 3A) is unlikely 
to be correct. It does not correspond to the electron dense cores found by 
TEM of the mRNA-LNPs. Currently, most researchers hold the view that 
Fig. 2. Cryo-TEM image of mRNA-LNP showing ‘bleb’ structures with distinctly 
different electron density. Adapted from Brader et al. (2021) with permission. 
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mRNA-LNPs are best described by the core–shell model (Fig. 3B & C). 
This means that the nanoparticles have a surface layer and an amor-
phous, isotropic core. Viger-Gravel et al. used NMR spectroscopy to 
elucidate an LNP structure and they make the case that two types of core 
are possible (Viger-Gravel et al., 2018). They describe the model of an 
amorphous core containing water pores surrounded by inverted cationic 
lipids (Fig. 3B). They also postulate that the lipids in the core could be 
homogeneously dispersed with small water pockets in between 
(Fig. 3C). The latter corresponds more to theexperimental results for 
their siRNA-LNPs and mRNA-LNPs. 
Arteta et al. based their mRNA-LNP structure-model on cryo-TEM, 
small-angle X-ray scattering (SAXS) and small-angle neutron scattering 
(SANS) measurements. They found that 1,2-distearoyl-sn-glycero-3- 
phosphocholine (DSPC) and PEG-lipid as well as part of the ionizable 
cationic lipid and cholesterol are located on the surface of the LNPs. 
Inside the core, the main part of the ionizable cationic lipid, cholesterol 
(dependent on its concentration), water and mRNA are present. Inter-
estingly, their research indicates that the isotropic LNP core consists for 
24% (volume fraction) of water. They propose that mRNA is located 
inside water cylinders, which are surrounded by cationic lipids (Fig. 4). 
This would mean that the mRNA is –at least partly– exposed to water 
inside the LNPs, which likely contributes to its instability upon storage 
under non-frozen conditions (Arteta et al., 2018). Comparable results 
were reported by Sebastiani et al. (2021). 
It would, therefore, be interesting to study how mRNA interacts with 
water and ionizable cationic lipids in the LNP. mRNA is hydrophilic; it 
can interact electrostatically and through hydrogen bonds with ioniz-
able cationic lipids (apparent pKa < 6.5) (Buschmann et al., 2021). This 
depends on the pH inside the LNP. If the LNP shells are permeable to 
protons –which is likely, as ionized dyes such as 2-(p-toluidino)-6-nap-
thalene sulfonic acid (TNS) and thionine can enter the LNP core 
(Jayaraman et al., 2012; Brader et al., 2021) – the pH would be similar to 
the rest of the formulation, around 7 to 8, meaning that most of the 
ionizable cationic lipids would be uncharged. However, as the ionizable 
cationic lipids are stacked in the core, they may show polyelectrolyte 
behavior, leading to deviations of the Henderson-Hasselbalch equation, 
i.e., ‘smearing out’ of the titration curve (Pierrat and Lebeau, 2015). 
Moreover, interaction between the mRNA and the ionizable cationic 
lipids might affect the ionization behavior. For siRNA only weak elec-
trostatic interactions were found with the ionizable cationic lipid, 
indicating that at least for siRNA-LNP formulations the pH inside ap-
proaches or equals the pH outside (Viger-Gravel et al., 2018). For 
mRNA-LNPs, no such experimental studies have been performed yet. A 
molecular dynamics simulation study of the complexation of mRNA and 
a cationic lipid demonstrated lipid-lipid cluster formation and lipid- 
mRNA cluster formation. Both electrostatic and hydrogen bonds were 
driving the cationic lipid and mRNA interactions (Rissanou et al., 2020). 
Another interesting finding by Arteta et al. is that the shell of their 
mRNA-LNPs is a monolayer (Arteta et al., 2018; Verbeke et al., 2019). 
Other researchers propose that the outer shell of mRNA-LNPs consists of 
one or multiple bilayers, based on cryo-TEM analysis (Fig. 2) (Patel 
et al., 2020; Tanaka et al., 2020) or SANS (Sebastiani et al., 2021). These 
findings indicate that assessment of the nature of the mRNA-LNP shell 
with these techniques is difficult and/or that multiple types of mRNA- 
LNP structures may exist, dependent on, e.g., the nature of the lipids 
and the preparation protocol for the mRNA-LNPs. This, in turn, could 
have implications for the stability of different formulations. In conclu-
sion, questions remain around the structure of mRNA-LNPs and the 
Fig. 3. Schematic representation of the proposed models for siRNA-LNP and mRNA-LNP structure. A: multilamellar vesicles; B: nanostructure core; C: homogeneous 
core shell as discussed by Viger-Gravel et al. (2018). Courtesy of the authors. 
Table 2 
Differences between mRNA and siRNA molecules.   
mRNA siRNA 
Molecular weight (g/mol) ≥ 106 104 
Molecular conformation Single stranded Double stranded 
5′ end 5′ cap Phosphorylated 5′ end 
3′ end Poly-A tail Hydroxylated 3′ end  
Fig. 4. Schematic representation of the mRNA-water cylinders in the core of 
mRNA- LNPs (Arteta et al., 2018). Courtesy of the authors. 
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interactions between the encapsulated mRNA and the various lipid 
components. 
Analysis of the components of the various mRNA-COVID-19 vaccines 
has shown that there are common features, but also significant differ-
ences (Table 1). The LNP formulation, the use of modified-nucleosides, 
the GC content and the differences in length between the conventional 
mRNA and SAM vaccines might influence the physical and chemical 
stability of these mRNA-COVID-19 vaccines during storage. 
3. In vitro stability of mRNA vaccines 
As mentioned in the introduction, one of the main obstacles for the 
distribution of the currently approved mRNA-COVID-19 vaccines is that 
they have to be stored in frozen form (cf. Crommelin et al., 2021). At 
refrigerator temperatures, 2–8 ◦C, the Pfizer/BioNTech and Moderna 
vaccines are stable for 5 and 30 days, respectively. Both companies 
provide detailed handling instructions for the end-user (EMA, 2020b, 
2021). Interestingly, the vaccine candidate by CureVac is reported to be 
stable for 3 months at refrigerator temperatures and at − 60 ◦C (CureVac, 
2020). These are the only manufacturers who have released their long- 
term storage conditions at present. Such temperature requirements 
severely impact the logistics of the storage, transport, and distribution of 
these vaccines. However, to date little information on optimization of 
the stability of mRNA vaccines can be found in the public domain. This 
section aims to give an overview of the factors that influence the stability 
of the components of mRNA-LNP vaccines and discuss the methods to 
analyze this stability. 
3.1. mRNA stability 
One factor that strongly influences the required storage conditions is 
the stability of the mRNA. As discussed above under Section 2.1, the 
structure of the mRNA molecule is specifically designed to increase the 
translation of the target antigen in vivo. A special feature of mRNA is that 
even one change (strand break, or oxidation of the bases) in the long 
mRNA strand (typically between 1000 and 5000 nucleotides long) can 
stop translation (Klauer and van Hoof, 2012). This makes mRNA vac-
cines quite different from other vaccines in which small changes of the 
antigens do not necessarily have a measurable effect on their efficacy. 
Consequently, for mRNA vaccines, it is critical to monitor the integrity 
of the full molecule. 
There are several ways in which mRNA degradation can occur; one 
can discern chemical and physical degradation. Chemical degradation 
encompasses the modifications of bonds in the mRNA molecule. Physical 
instability includes denaturation (loss of secondary and tertiary struc-
ture), which has different –likely less significant– consequences for the 
activity of mRNA than denaturation has for the activity of protein bi-
ologics. However, denaturation also comprises processes such as ag-
gregation and precipitation, which negatively affect mRNA translation. 
In a review on the stability of nucleic acids Pogocki and Schöneich state 
that chemical degradation plays a larger role in the degradation of small 
nucleic acids than physical instability and that is probably even more 
true for large structures such as mRNA (Pogocki and Schöneich, 2000). 
Chemical degradation of mRNA in vitro mainly occurs through hy-
drolysis and oxidation. Hydrolysis predominantly occurs via the phos-
phodiester bonds that form the backbone of the mRNA molecule (Fig. 5). 
The 2′ OH group on the ribose plays a crucial role as the trans-
esterification reaction leading to a mRNA strand break starts by a 
nucleophilic attack by the 2′OH group on the phosphate ester bond 
leading to a break at the P-O5′ ester bond (Fig. 5). This process requires 
water and can be catalyzed by nucleases, but also by the mRNA molecule 
itself and other exogenous factors like Brønsted acids and bases 
(Houseley and Tollervey, 2009; Pogocki and Schöneich, 2000). In two 
publications on mRNA hydrolysis the authors state that the base 
sequence and secondary structure of mRNA influence the rate of hy-
drolysis (Kaukinen et al., 2002; Mikkola et al., 2001). Specifically, base- 
stacking may decrease the cleavage rate of phosphodiester bonds. The 
‘average unpaired probability’ of an mRNA molecule can be minimized. 
Specially designed algorithms that select nucleotide sequences for single 
stranded mRNA with maximum double stranded regions are available. 
In vitro stability is claimed to be significantly improved following this 
approach (Wayment-Steele et al., 2020). A difference between the 
CureVac, Pfizer/BioNTech and Moderna vaccines is that the latter two 
have single nucleoside incorporations of 1-methyl-pseudouridine. A 
previous study has shown that this modification improves RNA sec-
ondary structure stability (Mauger et al., 2019). CureVac uses GC- 
enrichment, which should have a similar effect (Hubert, 2021; Zhang 
et al., 2011). 
Oxidation, in contrast, affects the nucleobases and to a lesser extent 
the sugar groups of the mRNA’s ribose units. Oxidation can lead to the 
cleavage of bases, strand break and the alteration of the secondary 
structure of the mRNA (Pogocki and Schöneich, 2000). However, as 
stated before, hydrolysis appears to be accepted as the main factor 
driving mRNA degradation (Fabre et al., 2014). 
3.2. Analyzing mRNA stability 
As the integrity and purity of the mRNA are essential to safeguard 
efficacy and safety of mRNA vaccines, it is important to have tools to 
monitor these aspects. There are various attributes of the mRNA mole-
cules that collectively determine whether the product can be used. The 
review by Poveda et al. highlights these attributes and briefly touches 
upon approaches that are used in general to measure and monitor them 
(Poveda et al., 2019). 
Table 3 provides a comprehensive list of analytical methods to 
determine and monitor quality attributes and stability of mRNA vaccine 
bulk drug substance and final drug product. Quality specifications for 
the presently accepted mRNA-LNP COVID-19 products are still not 
available in the public domain. Leaked documents (through a cyber- 
attack of the EMA, just before the approval date in the UK and the 
Fig. 5. Base-catalyzed intramolecular hydrolysis of the phosphodiester bond in RNA by way of a 2′,3′-cyclic phosphate. B denotes a Brønsted base. Redrawn from 
Pogocki and Schöneich (2000). 
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USA), which contain classified information on the quality of Comirnaty, 
mention percentages of mRNA integrity between 70 and 75% (Tinari, 
2021) and the assessment report from the EMA reads: ’the quality of this 
medicinal product, submitted in the emergency context of the current 
(COVID-19) pandemic, is considered to be sufficiently consistent and 
acceptable.’ 
Here we elaborate on the techniques that are applicable for studying 
the integrity of mRNA and used for quality control (QC). An overview of 
quality documentation required by EU authorities for an Investigational 
Medicinal Products Dossier (IMPD) with a focus on mRNA vaccines is 
given by Schmidt and the interested reader is referred to that informa-
tive document for details (Schmid, 2017). Because many of the 
described methods are intended for assaying naked mRNA, whereas 
mRNA vaccines for COVID-19 are encapsulated in LNPs, for some assays 
the mRNA first needs to be released and isolated from the LNP. Potential 
effects of this isolation process can be taken into account by including 
proper controls. 
Gel electrophoresis is a frequently used technique that can give in-
formation on the size and the integrity of the mRNA. When mRNA de-
grades and strand breaks occur, the mRNA strand becomes shorter. As a 
result, the intensity of the band at the expected mRNA length will 
decrease or the band will broaden, while new bands may appear. Using 
this approach Démoulins et al. analyzed the quality of SAM under RNase 
free conditions (Démoulins et al., 2017). Based on the gel electropho-
resis data, they were able to determine whether the mRNA is of 
acceptable quality and stable. Commercial electrophoresis equipment is 
now available for high-throughput analysis of mRNA (Pocernich et al., 
2019). 
Recently, Zhang et al. showed that fluorescence correlation spec-
troscopy (FCS) can be used to monitor changes in mRNA size (H. Zhang 
et al., 2020). The Brownian motion of fluorescent mRNA gives an 
indication of its molecular weight. This technique, however, needs a 
fluorescent label, is not more accurate than gel electrophoresis and only 
detects mRNA degradation involving substantial changes in molecular 
weight, e.g., strand breaks. 
Throughout the (bio)pharmaceutical industry chromatographic 
techniques form a powerful platform to monitor purity and stability of 
active pharmaceutical ingredients and drug products. However, the 
development of HPLC techniques for establishing purity and stability of 
mRNA molecules has been slow so far. Successful protocols for analyzing 
large mRNA molecules can be found in the patent literature as well as in 
publications where RP-HPLC, SE-HPLC, IP-HPLC and IEX-HPLC methods 
are described (Issa and Packer, 2019; Kanavarioti, 2019; Spivak et al., 
2014). Some of these techniques can also be used for mRNA purification 
purposes (Kim et al., 2007; Levine et al., 2019). IEX-HPLC can be used 
for measuring free and LNP encapsulated mRNA. An orthogonal tech-
nique to establish the same parameter is the earlier mentioned Ribo-
Green technique. Different outcomes, however, were found for the same 
mRNA-LNP product; the IEX-HPLC outcome correlated better with the in 
vivo readout than the RiboGreen data. This illustrates that even estab-
lished techniques like the RiboGReen assay should be carefully validated 
on a case-by-case basis (Schariter et al., 2019). 
mRNA degradation can also be analyzed by using the reverse tran-
scription quantitative polymerase chain reaction (RT-qPCR). This 
approach quantifies the total amount of mRNA that can be transcribed 
into intact cDNA targets for PCR. This means that all degradation that 
prevents this can be quantified indirectly. In their evaluation of this 
technique, Brisco and Morley argue that it gives reliable quantitative 
results (Brisco and Morley, 2012). Another advantage of this method is 
that all types of degradation that affect transcription are taken into ac-
count, whereas the previously discussed techniques only look at mRNA 
size. However, RT-qPCR sometimes is less reliable due to the error rate 
of the enzymes that are used (Schmid, 2017). Other disadvantages of this 
approach are that it is not widely used and the different types of 
degradation cannot be distinguished from each other. 
mRNA expression in vitro (in cells) is also used to analyze the 
integrity of mRNA (Zhang et al., 2020b; Zhao et al., 2020). By using 
mRNA that encodes a fluorescent protein, the mRNA integrity can 
indirectly be determined by measuring the fluorescence signal. This 
approach can assist in providing guiding principles for bioactive mRNA- 
LNP design and formulation development studies. Alternatively, the 
translation efficacy of mRNA encoding non-fluorescent antigens can be 
determined using an enzyme-linked immunosorbent assay (ELISA), or 
western blotting techniques as has been used previously to analyze the 
stability of mRNA encoding the receptor-binding domain (RBD) of 
SARS-CoV-2 (Zhang et al., 2020b). Advantages of this approach are that 
it gives the sum of the overall integrity of the formulation and every-
thing that can influence the transcription of the mRNA. Disadvantages of 
this method are that it is not very precise, unable to show the type of 
mRNA damage, and time-consuming. 
Table 3 
Assays to determine and monitor mRNA drug substance and mRNA-LNP drug 
product quality attributes and stability.1)  
Assay2) Attribute 
Characterizing DNA templates and 
RNA transcripts  
DNA template sequencing/mRNA 
sequencing 
Identification of mRNA 
UV spectroscopy (A260 nm, A260/A280, 
A260/A230) 
Quantification - purity dependent 
Fluorescence-based assays (e.g., residual 
DNA) 
Quantification – purity dependent 
Agarose/acrylamide electrophoresis Molecular mass, RNA integrity and 
quantification 
Reverse transcriptase qPCR Identification and quantification of 
mRNA 
Western blot for dsRNA Quality assessment 
mRNA capping analysis Quality assessment 
mRNA polyadenylated tail analysis Quality assessment 
Chromatographic assays: RP-HPLC, SE- 
HPLC, IP-HPLC and IEX-HPLC 
Quantity and quality assessment 
Characterizing mRNA-encoded 
translation products  
In vitro translation - cell free medium Translation into target protein 
Messenger RNA evaluation using various 
cell-based systems 
Translation product analysis and 
potential toxicity assay 
Characterizing mRNA-lipid complexes  
DLS Particle size (distribution) 
Laser Doppler electrophoresis Zeta potential 
NTA/TRPS Particle size (distribution) 
SE-HPLC(-MALS) Particle size distribution; assessing 
bound/unbound mRNA 
Microscopy (cryo TEM, ESEM, AFM) Nanoparticle morphology, particle size 
(distribution) 
Gel or capillary electrophoresis Assessing bound/unbound mRNA and 
surface charge 
Chromatographic assays: RP-HPLC, SE- 
HPLC, IP-HPLC and IEX-HPLC / mass 
spectrometry 
Quantification and integrity of lipids 
and/or mRNA; for some: assessing 
bound/unbound mRNA and molar mass 
Fluorescent dyes Encapsulation efficiency 
General pharmaceutical tests   
Appearance, pH, osmolality, endotoxin 
concentration, sterility  
1) Adapted from Poveda et al, 2019; Muralidhara et al., 2016; Fan et al., 2021; 
Crommelin et al., 2021. 
2) Abbreviations: AF4, asymmetrical flow field-flow fractionation; AFM, 
atomic force microscopy; dsDNA, double stranded DNA; DLS, dynamic light 
scattering; ESEM, environmental scanning electron microscopy; IEX-HPLC, ion- 
exchange high performance liquid chromatography; IP-HPLC, ion-pair high 
performance liquid chromatography; MALS, multi-angle light scattering; NTA, 
nanoparticle tracking analysis; qPCR, quantitative polymerase chain reaction; 
RP-HPLC, reversed-phase high performance liquid chromatography; SE-HPLC, 
size-exclusion high performance liquid chromatography; TEM, transmission 
electron microscopy; TRPS, tunable resistive pulse sensing. 
L. Schoenmaker et al.                                                                                                                                                                                                                          
International Journal of Pharmaceutics 601 (2021) 120586
8
3.3. LNP stability 
Besides mRNA integrity, stability of LNPs is critical for the quality of 
mRNA-LNP vaccines. No information on LNP stability tests could be 
found for the present mRNA COVID-19 vaccines, but the siRNA-LNP 
formulation of Onpattro (patisaran) has a three-year shelf life when 
kept between 2◦ and 8 ◦C (EMA, 2018). There is a warning in this SMPC 
text that the dispersion should not be frozen. The composition of the 
Onpattro LNP system is: DLin-MC3-DMA, as ionizable cationic lipid: 
DSPC: cholesterol: PEG2000-C-DMG (see table 1) (mol-ratio 
50:10:38.5:1.5 mol%); they are composition-wise similar to the LNPs in 
Comirnaty and mRNA-1273. A study on siRNA-LNPs composed of the 
lipidoid 306O13 instead of DLin-MC3-DMA, showed that in aqueous 
conditions the formulation remained stable at 2 ◦C for 156 days at pH 7 
(Ball et al., 2016). Particle size and siRNA encapsulation for this 
formulation did not significantly change. Complementary research by 
Suzuki et al. showed that siRNA-LNPs are stable over the experimental 
period, i.e. 1.5 years, at 4 ◦C (Suzuki et al., 2015). Altogether, these data 
strongly indicate that instability of the mRNA, rather than LNP insta-
bility, determines the storage conditions and shelf life of the current 
mRNA-LNP COVID-19 vaccines. 
The stability and quality attributes of liposomes and LNPs have been 
reviewed by Fan et al. (Fan et al., 2021). LNPs can undergo chemical and 
physical instability. Chemical instability comprises the degradation of 
the lipids in the LNPs that are susceptible to hydrolysis and oxidation. 
Lipid oxidation can occur in unsaturated fatty acid moieties (not present 
in Comirnaty and mRNA-1273) and with cholesterol, potentially as a 
result of a hydroperoxide attack, an impurity present in the PEG-group 
of PEG2000-C-DMG (Jaeger et al., 1994; Wang et al., 2019). Oxidative 
impurities may also result in oxidation of encapsulated mRNA. The 
carboxylic ester bonds in lipids, such as DSPC and the ionizable cationic 
lipids, are susceptible to temperature- and pH-dependent hydrolysis 
(Fig. 6). 
Another key aspect of LNP stability is physical degradation. There 
are three main types of physical instability that can occur: aggregation, 
fusion, and leakage of the encapsulated pharmaceutical ingredient. 
Aggregation of LNPs during storage and fusion of LNPs has been re-
ported (Ayat et al., 2019; Ball et al., 2016). To increase stability on the 
shelf, LNPs are often formulated with PEG-lipids (Burke et al., 2013; 
Ryals et al., 2020). The PEG-molecules at the surface prevent the indi-
vidual LNPs from aggregating. The other type of physical degradation 
–leakage of the mRNA– mainly affects the stability of the encapsulated 
product. Of note, encapsulation efficiencies are typically > 90% and 
release of the RNA payload from LNPs during storage has not been re-
ported (as measured with the RiboGreen test). mRNA that is not 
encapsulated (‘naked mRNA’) is hardly taken up by cells; besides, it 
degrades rapidly and is, therefore, not available for translation. 
Hypersensitivity reactions –rarely observed upon intramuscular 
injection of the mRNA-LNP COVID-19 vaccines– may be related to the 
PEG-lipids. Therefore, alternative lipids to prevent aggregate formation 
have been investigated. Introduction of polysarcosine-modified lipids 
stabilized lipid-based systems against aggregation while reducing the 
immunostimulatory response (Nogueira et al., 2020). Additional testing 
is needed to establish whether such PEG-lipid alternatives improve the 
mRNA stability (e.g., owing to lack of peroxides). 
3.4. Analyzing LNP stability 
Analytical methods to monitor the stability of LNPs have been 
expertly reviewed in the previously mentioned article by Fan et al. and 
Kim et al. and we refer the interested reader to this literature source (Fan 
et al., 2021; Kim et al., 2021). 
3.5. Which mRNA-LNP component is more unstable: The mRNA, the 
lipids, or the combination? 
To date, several studies have investigated ways to stabilize mRNA 
and to stabilize LNPs during storage (Ball et al., 2016; Jones et al., 
2007). It is, however, interesting to question which of these components 
is the bottleneck for stability. Is it the mRNA that degrades when the 
mRNA-LNP formulations are not frozen, are the LNPs causing the 
problem, or is it the combination of mRNA with the LNPs? 
LNP systems entrapping chemically modified and highly stable 
siRNA molecules (e.g. Onpattro) have significantly longer shelf lives as 
compared to mRNA-LNP systems. This would suggest that not the LNP, 
but rather the mRNA is the current stability bottleneck. 
To date, there is no research report available in the public domain on 
the integrity of both mRNA and LNPs in mRNA-LNP formulations. In the 
few studies in which the effect of storage is investigated, such as the 
research by Zhang et al. (N.-N. Zhang et al., 2020), long-term effects are 
not measured. Therefore, we will be looking first at the long-term sta-
bility of naked mRNA, with the caveat that this may be different from 
the stability of mRNA encapsulated in LNPs (see below). 
In their review Pascolo et al. remark that aqueous solutions of naked 
mRNA can be stored at 4 ◦C for only a few days, provided that the mRNA 
is protected from degradation by contaminating ribonucleases by an 
RNase inhibitor (Pascolo, 2008). This seems to be in line with the cur-
rent view of mRNA instability. The existing body of research on the long- 
term stability of naked mRNA suggests that mRNA needs to be frozen or 
dried in order to stay stable for longer periods of time. 
In 2009, Roesler et al. show that the translation efficacy of mRNA 
encoding luciferase begins to decrease after 8 days or 16 days when 
stored –RNAse free– at room temperature as a liquid or in a lyophilized 
form, respectively. No efforts were made to optimize the formulations in 
terms of excipients and freeze drying conditions (Fig. 7) (Roesler et al., 
2009). Conclusions about the long-term stability at refrigerator 
Fig. 6. Lipids used in the mRNA-LNP COVID-19 vaccines BNT162b2 (Comirnaty) and mRNA-1273.  
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temperatures can not been drawn from this study, as the stability was 
only followed for 32 days. There is also information based on theoretical 
cleavage rate calculations. Wayment-Steele et al. predict that mRNA 
(4000 nt) will have a half-life of 941 days when it is stored at pH 7.4 and 
5 ◦C (Wayment-Steele et al., 2020). They do note that longer mRNA 
sequences, such as SAMs, are more prone to hydrolysis. Because this is a 
theoretical calculation that is only based on hydrolytic degradation ki-
netics, it might underestimate mRNA degradation, e.g., when trace 
amounts of RNase are present. More research into the stability of mRNA 
would have to be done to find a definitive answer. 
Together, these studies indicate that in an aqueous solution mRNA 
likely is less stable than LNPs. However, it should be reiterated that 
results on these two components in isolation could differ from the sit-
uation of mRNA encapsulated by LNPs. As discussed in previous sec-
tions, mRNA is located inside the LNP core together with an ionizable 
cationic lipid, cholesterol and water (cf. Fig. 4) (Arteta et al., 2018). This 
would mean that the mRNA is in an aqueous environment and therefore 
is susceptible to hydrolysis. The mechanisms of hydrolysis might then be 
similar to those for mRNA in solution (Brader et al., 2021). However, on 
the other hand, mRNA inside the LNPs may be coated by the ionizable 
lipid through hydrophobic, hydrogen-bond and/or electrostatic in-
teractions. In that case the mRNA might be more stable than naked 
mRNA dissolved in an aqueous medium. Without further studies, it can 
only be concluded that mRNA instability dictates storage conditions and 
drives the search for improved, more stable formulations. 
3.6. Reasons for different storage conditions 
Another interesting aspect of the current mRNA vaccines is that the 
reported storage temperatures and corresponding ‘shelf lives’ vary 
widely: from − 80 ◦C to 2–8 ◦C and from days to months (Crommelin 
et al., 2021). Is it possible to identify a difference in the formulation of 
the mRNA vaccines that could cause this variation? Or, could the dif-
ference in storage conditions be related to the limitations of the ther-
mostability testing protocol or a more guarded approach (Schmid, 
2017)? This information is important, as insights into the factors that 
positively affect the stability may be an interesting starting point for the 
future design of thermostable mRNA vaccines. 
Tom Madden, the CEO of Acuitas Therapeutics, stated that the 
Moderna and Pfizer/BioNTech mRNA vaccines likely have the same 
stability (Dolgin, 2020). Is it possible that the latter use a more con-
servative approach to ensure stability? Still, it is quite likely that the 
Pfizer/BioNTech mRNA-LNP vaccine, that currently has to be stored 
between − 60 to − 80 ◦C was also tested at higher temperatures and 
under refrigerated conditions as done by CureVac scientists (Stitz et al., 
2017). Moreover, the analysis techniques in the stability tests could 
differ in sensitivity as could the acceptance criteria. Publication of the 
stability study reports would provide the answers and it would be 
interesting to run comparative studies. 
4. Opportunities for improving shelf life & storage conditions 
When freezing is needed to keep a vaccine stable, distribution, 
storage and handling by the end-user are highly protocolized and costs 
increase. For distribution purposes, vaccine stability at refrigerator 
temperatures, 2–8 ◦C, would be a desired improvement. In the following 
section we will focus on research to achieve such storage conditions, as 
these are seen as a considerable inconvenience for large scale use of 
mRNA vaccines, such as in the COVID-19 pandemic. 
4.1. Excipients 
The conclusion from the previous section on the stability of mRNA 
vaccines is that in order to create more stable mRNA-LNP vaccines, 
stabilizing the mRNA is the first target. Obviously, any excipient used for 
mRNA-based vaccines must be RNase free. A review by Muralidhara 
et al. captures a lot of information on the impact of excipients and 
formulation milieu (Muralidhara et al., 2016). 
Some of the excipients proposed by Muralidhara et al. are already 
used in the mRNA vaccines by Moderna and Pfizer/BioNTech. Excipi-
ents in the formulations serve as buffers, osmolytes and cryoprotectant 
or have a dual effect. Moderna, for example, uses a Tris–HCl buffer that 
would have an additional stabilizing effect on nucleic acid macromol-
ecules as it is also a hydroxyl radical scavenger (EMA, 2021). When 
selecting these excipients, one should keep in mind that the product may 
need to be stored at sub-zero temperatures and excipients affect that 
milieu. The choice of the buffering system and osmolyte is important as 
the pH may change upon freezing, as has been shown for sodium 
phosphate buffered systems; a 3.5 pH-units drop occurs upon freezing. 
Histidine buffers are more ‘pH-resistant’ upon freezing. But still, the pH 
may drop 0.5 unit when cooling from 0 ◦C to − 30 ◦C (Kolhe et al., 2010). 
And, another example, NaCl (osmolyte)-solutions have a eutectic tem-
perature of − 21 ◦C. Other excipients that could be added are antioxi-
dants, non-reducing free radical scavengers (e.g., ethanol) or metal 
chelators (Evans et al., 2000). However, the question remains to what 
extent they indeed ameliorate the stability of mRNA-LNP formulations 
during storage below or above 0 ◦C. 
pH optimization is also important for mRNA vaccine stability, as the 
pH influences the hydrolysis rate of mRNA and also LNP stability. 
Generally, mRNA is most stable in a weakly basic environment. The pH 
of the Moderna and Pfizer/BioNTech vaccines is between 7 and 8. 
Wayment-Steele et al. make the point that the apparent pH at the surface 
of the cationic, fully charged lipids could be higher than in the imme-
diate surrounding aqueous medium (Wayment-Steele et al., 2020). 
Fig. 7. Stability of mRNA in water analysed by luciferase expression in transfected BHK-21 cells. Courtesy of Roesler et al. (2009).  
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4.2. Lyophilization 
As the presence of water initiates degradation reactions in mRNA- 
LNPs, lyophilization would be a logical step to improve the long-term 
stability of mRNA-LNP formulations. The head of viral vaccines 
research at Pfizer, Philip Dormitzer, has already mentioned Pfizer’s 
aspiration to use lyophilization for mRNA-LNP SARS-CoV-2 vaccines 
(Dolgin, 2020). Moreover, a lyophilized form of a mRNA-based cyto-
megalovirus vaccine (mRNA-1647) is used in a phase 2 clinical trial. It 
has a claimed shelf life at 5 ◦C of ≥ 18 months. However, no details on 
the formulation and production process can be found in the public 
domain (Moderna, 2021). 
Freeze drying is widely used for live, attenuated virus vaccines 
(Hansen et al., 2015). It has also already been investigated for naked 
mRNA formulations, demonstrating its applicability and beneficial ef-
fect on mRNA stabilisation. Previous research by Jones et al. shows that 
freeze-dried mRNA formulated with trehalose is stable at 4 ◦C for up to 
10 months (Jones et al., 2007). Lipid nanoparticles can be successfully 
freeze dried as well. During the freeze-drying process the structures are 
exposed to stress. Therefore, lyoprotectants that stabilize these colloidal 
particles should be included in the formulation. Sucrose or trehalose are 
used for that purpose (Abdelwahed et al., 2006). Thus, the studies with 
either mRNA or with LNPs suggest that lyophilization could be a 
possible way to increase the stability of the combination, mRNA-LNP, 
and could thereby allow for storage at higher temperatures than those 
currently required. However, lyophilization does have its downsides, as 
it requires reconstitution before administration and is a relatively 
expensive, energy- and time-consuming process. On the other hand, 
keeping the mRNA vaccines (deep)frozen also comes at a cost. There-
fore, a logical next step is to investigate whether lyophilization is a 
viable option for mRNA-LNP formulations. 
Shirane et al. freeze dried the ethanol-containing siRNA-LNP 
dispersion obtained immediately after LNP formation and found no 
difference between the gene knockdown efficiency of the freshly pre-
pared (ethanol removed by ultrafiltration) and the reconstituted freeze- 
dried formulations in vivo (Shirane et al., 2018). These results show 
promise for the feasibility of lyophilization of mRNA-LNPs, while 
recognizing the structural differences between siRNA and mRNA. 
There is little published data on the lyophilization of mRNA-LNPs, 
but there is one recent paper by Zhao et al. studying mRNA lipid-like 
nanoparticles (Zhao et al., 2020). They studied the effect of freeze- 
drying of these nanoparticles that contain an ionizable cationic lipid- 
like molecule. No details of the -freeze-drying process are provided. 
Contrary to the data on siRNA-LNPs obtained by Shirane et al., they 
found that after lyophilization and reconstitution the in vitro test showed 
no loss of activity, but the in vivo efficiency was lost. Thus, freeze-drying 
of mRNA-LNPs might be a more difficult task than previous research 
suggests. It would be helpful to elucidate the mechanism behind this 
nullification of in vivo efficiency. It could, for example, be that the 
formulation was suboptimal for freeze-drying or that the lyophilization 
process itself was flawed. The authors speculate that an alteration in the 
nanostructure of the mRNA-LLPs may have caused the low in vivo effi-
cacy, as such a change could affect properties like the binding to serum 
proteins, which are absent in the in vitro study. Therefore, further 
improvement of the formulation excipients and freeze-drying conditions 
might lead to successful lyophilization of mRNA-LLPs. 
Another approach, in case lyophilization of the fully prepared 
mRNA-LNPs complex is problematic, is to lyophilize naked mRNA and 
combine it with the LNPs shortly before administration. Ball et al. suc-
cessfully followed the opposite approach by reconstituting freeze dried 
LNPs with siRNA/ethanol solutions (Ball et al., 2016). They correctly 
pointed out that: ‘Unfortunately, the addition of ethanol to reconstitu-
tion solutions is often neither convenient nor practical, as dialysis into 
aqueous buffer would be required before use in animals or in the clinic’ 
If one wishes to avoid freeze drying or organic solvents for the genera-
tion of active mRNA-LNPs, one may mix an ’empty’ LNP aqueous 
suspension with ’fresh’ mRNA and find that the mRNA is taken up and 
active (Leavitt et al., 2020). 
Apart from challenges to preserve the integrity of mRNA-LNP 
through lyophilization, there are other hurdles such as the high en-
ergy consumption of the process and other costs, e.g., those related to 
the necessary, dramatic expansion of the lyophilization capacity 
worldwide in times of a pandemic. Therefore, it is worthwhile to 
consider alternative drying techniques. Only one publication could be 
found on spray drying of mRNA-LNPs where polymers (e.g., Eudragit) 
were needed as stabilizers for mRNA-LNPs to secure translation effi-
ciency in vivo (Karve et al., 2020). Supercritical drying techniques would 
be another alternative for freeze-drying; they have been shown to be 
feasible –with their pros and cons– for other macromolecular biotech 
products, such as proteins (Jovanović et al., 2004). 
5. Conclusions and prospects 
This review outlines how different aspects of the current mRNA 
vaccine formulations influence their stability during storage. We 
conclude that exposure of mRNA to water likely is the main factor for 
mRNA vaccine instability. An implication of this is that decreasing the 
exposure to water would be a promising approach for improving mRNA 
vaccine stability. 
The studies on mRNA-LNP structures indicate that the mRNA is 
located in the core of LNPs together with ionizable cationic lipid and 
water. This raises important questions about the possible shielding of the 
mRNA from water. It is, for example, unknown if and how the ionizable 
cationic lipids in the LNP interact with the mRNA. More work needs to 
be done to confirm the proposed structure and to understand the con-
sequences. For instance, the pH inside the LNPs has been identified as an 
important characteristic to study in relation to stability. Another object 
of study would be to specifically analyze the type(s) of degradation that 
mRNA molecules undergo in their final formulation and whether 
sequence adjustment could help to maintain strand integrity. This could 
then also be coupled to characterization and optimization of the sec-
ondary and tertiary structure of mRNA, as there are indications that 
some folded structures are more stable. 
This report is the first comprehensive survey of the factors behind 
mRNA-LNP vaccine instability. It also points towards solutions to 
address this instability and thereby may be of assistance to the devel-
opment of more thermostable mRNA-LNP vaccines, alleviating a major 
barrier for the distribution of these vaccines. 
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Sahin, Ugur, Karikó, Katalin, Türeci, Özlem, 2014. MRNA-based therapeutics — 
developing a new class of drugs. Nat. Rev. Drug Discov. 13 (10), 759–780. https:// 
doi.org/10.1038/nrd4278. 
Schariter, J., Hassett, K., Smith, M., Almarsson, O., Brito, L., 2019. METHODS OF 
MAKING LIPID NANOPARTICLES. WO/2019/046809. 
Schmid, A., 2017. Considerations for producing mRNA vaccines for clinical trials BT - 
RNA vaccines: methods and protocols. In: Kramps, T., Elbers, K. (Eds.), RNA 
Vaccines. Springer, New York, New York, NY, pp. 237–251. https://doi.org/ 
10.1007/978-1-4939-6481-9_15. 
Sebastiani, F., Yanez Arteta, M., Lerche, M., Porcar, L., Lang, C., Bragg, R.A., Elmore, C. 
S., Krishnamurthy, V.R., Russell, R.A., Darwish, T., Pichler, H., Waldie, S., 
Moulin, M., Haertlein, M., Forsyth, V.T., Lindfors, L., Cárdenas, M., 2021. 
Apolipoprotein E binding drives structural and compositional rearrangement of 
mRNA-containing lipid nanoparticles. ACS Nano. https://doi.org/10.1021/ 
acsnano.0c10064. 
Shirane, Daiki, Tanaka, Hiroki, Nakai, Yuta, Yoshioka, Hiroki, Akita, Hidetaka, 2018. 
Development of an alcohol dilution-lyophilization method for preparing lipid 
nanoparticles containing encapsulated siRNA. Biol. Pharm. Bull. 41 (8), 1291–1294. 
https://doi.org/10.1248/bpb.b18-00208. 
Spivak, V.B., Sharokh, Z., Issa, W.J., 2014. ANALYSIS OF MRNA HETEROGENEITY AND 
STABILITY. WO 2014/144711. 
Stitz, Lothar, Vogel, Annette, Schnee, Margit, Voss, Daniel, Rauch, Susanne, 
Mutzke, Thorsten, Ketterer, Thomas, Kramps, Thomas, Petsch, Benjamin, 
Rupprecht, Charles E., 2017. A thermostable messenger RNA based vaccine against 
rabies. PLoS Negl. Trop. Dis. 11 (12), e0006108. https://doi.org/10.1371/journal. 
pntd.0006108. 
Suzuki, Y., Hyodo, K., Tanaka, Y., Ishihara, H., 2015. siRNA-lipid nanoparticles with 
long-term storage stability facilitate potent gene-silencing in vivo. J. Control. 
Release 220, 44–50. https://doi.org/10.1016/j.jconrel.2015.10.024. 
Tanaka, Hiroki, Takahashi, Tatsunari, Konishi, Manami, Takata, Nae, Gomi, Masaki, 
Shirane, Daiki, Miyama, Ryo, Hagiwara, Shinya, Yamasaki, Yuki, Sakurai, Yu, 
Ueda, Keisuke, Higashi, Kenjirou, Moribe, Kunikazu, Shinsho, Eiji, Nishida, Ruka, 
Fukuzawa, Kaori, Yonemochi, Etsuo, Okuwaki, Koji, Mochizuki, Yuji, Nakai, Yuta, 
Tange, Kota, Yoshioka, Hiroki, Tamagawa, Shinya, Akita, Hidetaka, 2020. Self- 
degradable lipid-like materials based on “hydrolysis accelerated by the intra-particle 
enrichment of reactant (HyPER)” for messenger RNA delivery. Adv. Funct. Mater. 30 
(34), 1910575. https://doi.org/10.1002/adfm.v30.3410.1002/adfm.201910575. 
Thess, Andreas, Grund, Stefanie, Mui, Barbara L, Hope, Michael J, Baumhof, Patrick, 
Fotin-Mleczek, Mariola, Schlake, Thomas, 2015. Sequence-engineered mRNA 
without chemical nucleoside modifications enables an effective protein therapy in 
large animals. Mol. Ther. 23 (9), 1456–1464. https://doi.org/10.1038/mt.2015.103. 
Tinari, S., 2021. The EMA covid-19 data leak, and what it tells us about mRNA 
instability. BMJ 372, n627. https://doi.org/10.1136/bmj.n627. 
Verbeke, Rein, Lentacker, Ine, De Smedt, Stefaan C., Dewitte, Heleen, 2019. Three 
decades of messenger RNA vaccine development. Nano Today 28, 100766. https:// 
doi.org/10.1016/j.nantod.2019.100766. 
Verbeke, R., Lentacker, I., De Smedt, S.C., Dewitte, H., 2021. The dawn of mRNA 
vaccines: the COVID-19 case. J. Control. Release. https://doi.org/10.1016/j. 
jconrel.2021.03.043. 
Viger-Gravel, Jasmine, Schantz, Anna, Pinon, Arthur C., Rossini, Aaron J., 
Schantz, Staffan, Emsley, Lyndon, 2018. Structure of lipid nanoparticles containing 
siRNA or mRNA by dynamic nuclear polarization-enhanced NMR spectroscopy. 
J. Phys. Chem. B 122 (7), 2073–2081. https://doi.org/10.1021/acs. 
jpcb.7b1079510.1021/acs.jpcb.7b10795.s001. 
Vogel, Annette B., Lambert, Laura, Kinnear, Ekaterina, Busse, David, Erbar, Stephanie, 
Reuter, Kerstin C., Wicke, Lena, Perkovic, Mario, Beissert, Tim, Haas, Heinrich, 
Reece, Stephen T., Sahin, Ugur, Tregoning, John S., 2018. Self-amplifying RNA 
vaccines give equivalent protection against influenza to mRNA vaccines but at much 
lower doses. Mol. Ther. 26 (2), 446–455. https://doi.org/10.1016/j. 
ymthe.2017.11.017. 
Wang, Changguang, Siriwardane, Dumindika A., Jiang, Wenlei, Mudalige, Thilak, 2019. 
Quantitative analysis of cholesterol oxidation products and desmosterol in 
parenteral liposomal pharmaceutical formulations. Int. J. Pharm. 569, 118576. 
https://doi.org/10.1016/j.ijpharm.2019.118576. 
Ward, D., McCormack, S., 2021. Clinical trial to assess the safety of a coronavirus vaccine 
in healthy men and women. ISRCTN. https://doi.org/10.1186/ISRCTN17072692. 
Wayment-Steele, H.K., Kim, D.S., Choe, C.A., Nicol, J.J., Wellington-Oguri, R., Sperberg, 
R.A.P., Huang, P.-S., Das, R., 2020. Theoretical basis for stabilizing messenger RNA 
through secondary structure design. bioRxiv Prepr. Serv. Biol. 2020.08.22.262931. 
https://doi.org/10.1101/2020.08.22.262931. 
L. Schoenmaker et al.                                                                                                                                                                                                                          
International Journal of Pharmaceutics 601 (2021) 120586
13
World Health Organization, 2021. Draft landscape and tracker of COVID-19 candidate 
vaccines [WWW Document]. accessed 3.18.21. https://www.who.int/publications/ 
m/item/draft-landscape-of-covid-19-candidate-vaccines. 
Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.-L., Abiona, O., Graham, B. 
S., McLellan, J.S., 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion 
conformation. Science (80-.). 367, 1260 LP – 1263. https://doi.org/10.1126/ 
science.abb2507. 
Zhang, Heyang, Rombouts, Koen, Raes, Laurens, Xiong, Ranhua, De Smedt, Stefaan C., 
Braeckmans, Kevin, Remaut, Katrien, 2020a. Fluorescence-based quantification of 
messenger RNA and plasmid DNA decay kinetics in extracellular biological fluids 
and cell extracts. Adv. Biosyst. 4 (5), 2000057. https://doi.org/10.1002/adbi. 
v4.510.1002/adbi.202000057. 
Zhang, J., Kuo, C.C.J., Chen, L., 2011. GC content around splice sites affects splicing 
through pre-mRNA secondary structures. BMC Genomics 12, 90. https://doi.org/ 
10.1186/1471-2164-12-90. 
Zhang, Na-Na, Li, Xiao-Feng, Deng, Yong-Qiang, Zhao, Hui, Huang, Yi-Jiao, Yang, Guan, 
Huang, Wei-Jin, Gao, Peng, Zhou, Chao, Zhang, Rong-Rong, Guo, Yan, Sun, Shi-Hui, 
Fan, Hang, Zu, Shu-Long, Chen, Qi, He, Qi, Cao, Tian-Shu, Huang, Xing-Yao, 
Qiu, Hong-Ying, Nie, Jian-Hui, Jiang, Yuhang, Yan, Hua-Yuan, Ye, Qing, Zhong, Xia, 
Xue, Xia-Lin, Zha, Zhen-Yu, Zhou, Dongsheng, Yang, Xiao, Wang, You-Chun, 
Ying, Bo, Qin, Cheng-Feng, 2020b. A Thermostable mRNA Vaccine against COVID- 
19. Cell 182 (5), 1271–1283.e16. https://doi.org/10.1016/j.cell.2020.07.024. 
Zhao, Boxuan Simen, He, Chuan, 2015. Pseudouridine in a new era of RNA 
modifications. Cell Res. 25 (2), 153–154. https://doi.org/10.1038/cr.2014.143. 
Zhao, Pengxuan, Hou, Xucheng, Yan, Jingyue, Du, Shi, Xue, Yonger, Li, Wenqing, 
Xiang, Guangya, Dong, Yizhou, 2020. Long-term storage of lipid-like nanoparticles 
for mRNA delivery. Bioact. Mater. 5 (2), 358–363. https://doi.org/10.1016/j. 
bioactmat.2020.03.001. 
L. Schoenmaker et al.                                                                                                                                                                                                                          
